Trial Profile
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2024
Price :
$35
*
At a glance
- Drugs I-131-Apamistamab (Primary) ; Asparaginase; Azacitidine; Carboplatin; Cladribine; Clofarabine; Cyclophosphamide; Cytarabine; Daunorubicin; Decitabine; Doxorubicin; Enasidenib; Etoposide; Fludarabine; Gemtuzumab ozogamicin; Gilteritinib; Idarubicin; Ivosidenib; Midostaurin; Mitoxantrone; Sorafenib; Tioguanine; Topotecan; Venetoclax
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms Iomab-B SIERRA; SIERRA; SIERRA in AML
- Sponsors Actinium Pharmaceuticals
- 18 Apr 2024 According to Actinium Pharmaceuticals media release, results from this trial were presented at the presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17.
- 18 Apr 2024 Results presented in an Actinium Pharmaceuticals Media Release.
- 01 Apr 2024 According to Actinium Pharmaceuticals media release, Results from this study have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society (EBMT) being held April 14 to 17, 2024, in Glasgow, Scotland.